Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Correlates of late HIV diagnosis: implications for testing policy.

Delpierre C, Dray-Spira R, Cuzin L, Marchou B, Massip P, Lang T, Lert F; VESPA Study Group.

Int J STD AIDS. 2007 May;18(5):312-7.

2.

High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population.

Delpierre C, Cuzin L, Lauwers-Cances V, Marchou B, Lang T; NADIS Group.

AIDS Patient Care STDS. 2006 Dec;20(12):838-47.

PMID:
17192149
3.
4.

Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation.

Lewden C, Jougla E, Alioum A, Pavillon G, Lièvre L, Morlat P, Salmon D, May T, Chêne G, Costagliola D; Mortalité 2000 Study Group.

Epidemiol Infect. 2006 Dec;134(6):1345-52. Epub 2006 May 11.

5.

Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.

Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, Lipman MC, Bhagani S, Phillips AN, Johnson MA.

AIDS. 2006 Jan 2;20(1):67-71.

PMID:
16327321
6.

No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002).

Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, Rice BD, Evans BG.

AIDS. 2005 Mar 25;19(5):513-20.

PMID:
15764857
7.

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Freedberg KA, Walensky RP.

N Engl J Med. 2005 Feb 10;352(6):586-95.

8.

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

N Engl J Med. 2005 Feb 10;352(6):570-85.

9.
10.

Late versus early testing of HIV--16 Sites, United States, 2000-2003.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2003 Jun 27;52(25):581-6.

11.

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR 3rd, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA.

Antivir Ther. 2002 Dec;7(4):257-66.

PMID:
12553480
12.

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH.

N Engl J Med. 2000 Mar 30;342(13):921-9.

13.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):499-508.

PMID:
10221527
14.

Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group.

Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, Zenilman J, Hoxworth T, Malotte CK, Iatesta M, Kent C, Lentz A, Graziano S, Byers RH, Peterman TA.

JAMA. 1998 Oct 7;280(13):1161-7.

PMID:
9777816
16.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.

Ann Intern Med. 1997 Jun 15;126(12):946-54.

PMID:
9182471

Supplemental Content

Support Center